Recent findings present evidence that the port delivery system with ranibizumab as a meaningful alternative treatment choice for patients with neovascular age-related macular degeneration (nAMD).
“The data suggest PDS treatment was a preference for all patients assigned to PDS over previous intravitreal injections in the Archway study, although both delivery methods had high treatment satisfaction, according to the investigators.” Via: HCPlive
GistMD is an Israeli, Tel-Aviv-based startup dealing with some of the difficulties related to intravitreal injections and how to make the procedure run smoothly. Gist’s system entails that a patient fills in a survey whose interface then creates a personalized educational video about the procedure based on the patient’s gender, age, prior conditions, and more. A 76-year-old patient who went through the intravitreal injection procedure after watching their personalized video said: “I really like that it [the video] explained the procedure properly and with humor. I’ve done the injections several times in the past year and it still managed to help me a lot. It’s fun that I was able to receive such a video right to my phone and better understand the procedure which I have undergone several times